Biovaxys and horizon technology finance corp execute amendment to asset purchase agreement ("apa")

The apa formalized the february 2024 biovaxys acquisition of the former imv inc. assets vancouver, bc , may 29, 2025 /prnewswire/ -- biovaxys technology corp. (cse: biov) (fra: 5lb) ("biovaxys" or the "company") is pleased to announce today that the company and horizon technology finance corporation ("horizon") have executed a follow-on amendment ("amendment") to the asset purchase agreement dated february 11th, 2024 ("apa") for acquiring the entire portfolio of assets and intellectual property based on the dpx™ immune educating platform technology developed by canadian biotechnology company, imv inc.  section 12 of the february 11 th, 2024 apa is a performance milestone provision for biovaxys to demonstrate an aggregate capital raise of usd $10m by december 31, 2024.  on december 9 th, 2024, horizon and biovaxys initially amended the apa by agreeing to delete the reference to "december 31, 2024" found in section 12 and replacing it with the date of "june 30, 2025.
APA Ratings Summary
APA Quant Ranking